Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary.
A monoclonal antibody (mAb) MY.1E12 was applied to detect MUC1 with sialylated glycans in a total of 55 formalin-fixed, paraffin-embedded surgical specimens of ovarian clear cell adenocarcinomas. A reverse correlation between the binding levels of this mAb and patient survival was demonstrated. To examine the role of MUC1 in ovarian clear cell carcinomas, two cDNA encoding MUC1 were transfected into ES-2 ovarian clear cell carcinoma cells. By comparing these cells, the role of MUC1 in tumorigenicity, chemosensitivity and survival under anoikis conditions were assessed. The results indicate that MUC1 expressed on ovarian clear cell carcinoma cells is causally involved in the malignant behavior.
Tamada
Yutaka
Y
Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan.
Takeuchi
Hideyuki
H
Suzuki
Nao
N
Susumu
Nobuyuki
N
Aoki
Daisuke
D
Irimura
Tatsuro
T
D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism; D000368:Aged; D000818:Animals; D023102:Anoikis / Q000187:drug effects / Q000502:physiology; D000911:Antibodies, Monoclonal; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D018396:Mucin-1 / Q000276:immunology*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism; D017239:Paclitaxel / Q000008:administration & dosage; D016612:Paraffin Embedding; D011379:Prognosis; D012794:Sialic Acids / Q000378:metabolism*; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D018396:Mucin-1; D012794:Sialic Acids; D017239:Paclitaxel; D002945:Cisplatin
Gynecol Oncol. 1993 May;49(2):250-4
8504995
Gastroenterology. 1994 Feb;106(2):353-61
7905449
J Clin Oncol. 1991 Jul;9(7):1138-50
1904477
J Biol Chem. 1990 Sep 5;265(25):15286-93
1697589
Cell Immunol. 1997 Mar 15;176(2):158-65
9073389
Cancer Res. 1993 Aug 15;53(16):3830-8
8339295
J Biol Chem. 1990 Sep 5;265(25):15294-9
2394722
Trends Biochem Sci. 1992 Sep;17(9):359-63
1412714
J Biol Chem. 2001 Apr 20;276(16):13057-64
11278868
Nat Med. 1996 Dec;2(12):1367-70
8946837
Mol Biol Cell. 1996 Apr;7(4):565-77
8730100
J Cell Biol. 1995 Apr;129(1):255-65
7698991
Annu Rev Physiol. 1995;57:607-34
7778880
Int J Cancer. 2000 Nov 15;88(4):507-18
11058865
Gynecol Oncol. 1989 Nov;35(2):199-203
2807010
J Biol Chem. 1993 Oct 5;268(28):21364-71
8407976
Oncol Res. 1999;11(5):233-41
10608618
Cancer Res. 1990 Jun 1;50(11):3331-8
2334927
Jpn J Cancer Res. 1996 May;87(5):505-11
8641988
J Cell Biol. 1994 Feb;124(4):619-26
8106557
Cancer. 2000 Jun 1;88(11):2584-9
10861437
Gynecol Oncol. 1990 Aug;38(2):203-9
2167280
J Immunol. 1993 Jul 15;151(2):767-76
7687622
Nat Med. 1998 Jan;4(1):43-9
9427605
Cancer Res. 1992 Apr 15;52(8):2318-24
1559234
Nature. 1978 Jun 1;273(5661):345-9
661946
Cancer. 1985 May 1;55(9):2019-25
3978582
N Engl J Med. 1993 Nov 18;329(21):1550-9
8155119
J Immunol Methods. 2002 Dec 15;270(2):199-209
12379325
J Biol Chem. 2001 Sep 21;276(38):35239-42
11483589
Obstet Gynecol. 1993 Jul;82(1):143-7
8515915
Trends Biochem Sci. 1990 Aug;15(8):291-4
2204153
J Pathol. 1997 Nov;183(3):311-7
9422987
Cancer Res. 1992 Nov 1;52(21):5985-90
1382849
Gynecol Oncol. 1998 Aug;70(2):255-8
9740700
Jpn J Cancer Res. 1996 May;87(5):488-96
8641986
Int J Cancer. 1998 May 4;76(3):377-82
9579575
Gynecol Oncol. 1995 Apr;57(1):33-46
7535723
Clin Cancer Res. 1995 Mar;1(3):333-42
9815989
Obstet Gynecol. 1998 May;91(5 Pt 1):783-92
9572231
Curr Opin Oncol. 1997 Nov;9(6):549-56
9370076
J Cell Sci. 1991 Dec;100 ( Pt 4):841-9
1814933
Cancer Res. 1991 Oct 1;51(19):5181-7
1717140